Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012
MALVERN, Pa., Nov. 1, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the third quarter 2012 on Wednesday, November 7, 2012 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter 2012. The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 10 a.m. ET on Wednesday, November 7, 2012. A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 10:00 a.m. ET on Wednesday, November 7, 2012. A question and answer session will follow the presentation.
Mr. Adrian Adams, Chief Executive Officer and President, will host the conference call.
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. GSK co-promotes Testim with Auxilium in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada. Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. An sBLA for XIAFLEX for the treatment of Peyronie's disease is expected to be submitted to the FDA by year end 2012. Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for CCH. For additional information, visit http://www.auxilium.com
AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to announce the third quarter 2012 results; and products in development for Peyronie's disease, including the expected filing of an sBLA, Frozen Shoulder syndrome and cellulite. Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties. A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, which are on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.